Study of Volrustomig as Monotherapy or in Combination with Anti- cancer Agents in Participants with Advanced/Metastatic Solid Tumors - eVOLVE-02

Exclusion Criteria

• Patients should not enter the study if any of the following exclusion criteria are fulfilled:
• 1. Spinal cord compression.
• 2. Brain metastases unless asymptomatic, stable, and not requiring steroids for at least 14 days prior to start of study intervention.
• 3. Participants with primary neuroendocrine, mesenchymal, sarcomatoid histologies, or other histologies not mentioned as part of the inclusion criteria.
• 4. Have not recovered (ie, ≤ Grade 1 or at baseline) from an AE due to a previously administered anti-cancer therapy.
• 5. For sub-study 2, have had radiotherapy within 2 weeks prior to enrollment.
• 6. History of another primary malignancy except for a) Malignancy treated with curative intent with no known active disease ≥2 years before the first dose of study intervention and of low potential risk for recurrence; b) Adequately treated nonmelanoma skin cancer or lentigo maligna, or carcinoma in situ without evidence of disease.
• 7. Any evidence of diseases, and/or history of organ transplant or allogenic stem cell transplant, which makes it undesirable for the participant to participate in the study or that would jeopardize compliance with the protocol.
• 8. Evidence of the following infections: active infection including tuberculosis; known HIV infection. that is not well controlled; active or uncontrolled HBV or HCV; or active hepatitis A.
• 9. Active or prior documented autoimmune or inflammatory disorders.
• 10. Participants who are candidates for curative therapy.
• 11. Prior exposure to any immune-mediated therapy.
• 12. Current or prior use of immunosuppressive medication within 14 days before the first dose of the study intervention is excluded. The following are exceptions to this criterion: a) Intranasal, inhaled, topical steroids, or local steroid injections (eg, intraarticular injection); b) Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication or chemotherapy premedication) or a single dose for palliative purpose (eg, pain control).
• 13. Receipt of the last dose of anti-cancer therapy 28 days prior to the first dose of study intervention or 5 half-lives of the respective agent, whichever is longer.
• 14. Any concurrent chemotherapy, radiotherapy, investigational, biologic, or hormonal therapy for cancer treatment.
• 15. Radiotherapy treatment with a wide field of radiation or to more than 30% of the bone marrow within 4 weeks, prior to the first dose of study intervention.
• 16. Major surgical procedures within 4 weeks prior to the first dose of the study intervention or still recovering from prior surgery.
• 17. Receipt of live attenuated vaccine within 30 days prior to the first dose of the study intervention.
• 18. Participants with a known allergy or hypersensitivity to the study intervention, or any excipients of the study intervention.